Plasma neuropeptide Y: A biomarker for symptom severity in chronic fatigue syndrome

Mary A. Fletcher, Martin Rosenthal, Michael H Antoni, Gail Ironson, Xiao R. Zeng, Zachary Barnes, Jeanna M. Harvey, Barry Hurwitz, Silvina Levis, Gordon Broderick, Nancy G. Klimas

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background: Chronic fatigue syndrome (CFS) is a complex, multi-symptom illness with a multisystem pathogenesis involving alterations in the nervous, endocrine and immune systems.Abnormalities in stress responses have been identified as potential triggers or mediators of CFS symptoms. This study focused on the stress mediator neuropeptide Y (NPY). We hypothesized that NPY would be a useful biomarker for CFS.Methods: The CFS patients (n = 93) were from the Chronic Fatigue and Related Disorders Clinic at the University of Miami and met the 1994 case definition of Fukuda and colleagues. Healthy sedentary controls (n = 100)) were from NIH or VA funded studies. Another fatiguing, multi-symptom illness, Gulf War Illness (GWI), was also compared to CFS. We measured NPY in plasma using a radioimmunoassay (RIA). Psychometric measures, available for a subset of CFS patients included: Perceived Stress Scale, Profile of Mood States, ATQ Positive & Negative Self-Talk Scores, the COPE, the Beck Depression Inventory, Fatigue Symptom Inventory, Cognitive Capacity Screening Examination, Medical Outcomes Survey Short Form-36, and the Quality of Life Scale.Results: Plasma NPY was elevated in CFS subjects, compared to controls (p = .000) and to GWI cases (p = .000). Receiver operating characteristics (ROC) curve analyses indicated that the predictive ability of plasma NPY to distinguish CFS patients from healthy controls and from GWI was significantly better than chance alone. In 42 patients with CFS, plasma NPY had significant correlations (<0.05) with perceived stress, depression, anger/hostility, confusion, negative thoughts, positive thoughts, general health, and cognitive status. In each case the correlation (+ or -) was in the anticipated direction.Conclusions: This study is the first in the CFS literature to report that plasma NPY is elevated compared to healthy controls and to a fatigued comparison group, GWI patients. The significant correlations of NPY with stress, negative mood, general health, depression and cognitive function strongly suggest that this peptide be considered as a biomarker to distinguish subsets of CFS.

Original languageEnglish
Article number76
JournalBehavioral and Brain Functions
Volume6
DOIs
StatePublished - Dec 29 2010

Fingerprint

Chronic Fatigue Syndrome
Neuropeptide Y
Biomarkers
Gulf War
Depression
Confusion
Equipment and Supplies
Neurobehavioral Manifestations
Endocrine System
Aptitude
Hostility
Anger
Psychometrics
ROC Curve
Cognition
Nervous System
Health Status
Radioimmunoassay
Fatigue
Immune System

ASJC Scopus subject areas

  • Behavioral Neuroscience
  • Biological Psychiatry
  • Cognitive Neuroscience
  • Medicine(all)

Cite this

Plasma neuropeptide Y : A biomarker for symptom severity in chronic fatigue syndrome. / Fletcher, Mary A.; Rosenthal, Martin; Antoni, Michael H; Ironson, Gail; Zeng, Xiao R.; Barnes, Zachary; Harvey, Jeanna M.; Hurwitz, Barry; Levis, Silvina; Broderick, Gordon; Klimas, Nancy G.

In: Behavioral and Brain Functions, Vol. 6, 76, 29.12.2010.

Research output: Contribution to journalArticle

Fletcher, Mary A. ; Rosenthal, Martin ; Antoni, Michael H ; Ironson, Gail ; Zeng, Xiao R. ; Barnes, Zachary ; Harvey, Jeanna M. ; Hurwitz, Barry ; Levis, Silvina ; Broderick, Gordon ; Klimas, Nancy G. / Plasma neuropeptide Y : A biomarker for symptom severity in chronic fatigue syndrome. In: Behavioral and Brain Functions. 2010 ; Vol. 6.
@article{c36e201ebcc1476685d1d6924f544966,
title = "Plasma neuropeptide Y: A biomarker for symptom severity in chronic fatigue syndrome",
abstract = "Background: Chronic fatigue syndrome (CFS) is a complex, multi-symptom illness with a multisystem pathogenesis involving alterations in the nervous, endocrine and immune systems.Abnormalities in stress responses have been identified as potential triggers or mediators of CFS symptoms. This study focused on the stress mediator neuropeptide Y (NPY). We hypothesized that NPY would be a useful biomarker for CFS.Methods: The CFS patients (n = 93) were from the Chronic Fatigue and Related Disorders Clinic at the University of Miami and met the 1994 case definition of Fukuda and colleagues. Healthy sedentary controls (n = 100)) were from NIH or VA funded studies. Another fatiguing, multi-symptom illness, Gulf War Illness (GWI), was also compared to CFS. We measured NPY in plasma using a radioimmunoassay (RIA). Psychometric measures, available for a subset of CFS patients included: Perceived Stress Scale, Profile of Mood States, ATQ Positive & Negative Self-Talk Scores, the COPE, the Beck Depression Inventory, Fatigue Symptom Inventory, Cognitive Capacity Screening Examination, Medical Outcomes Survey Short Form-36, and the Quality of Life Scale.Results: Plasma NPY was elevated in CFS subjects, compared to controls (p = .000) and to GWI cases (p = .000). Receiver operating characteristics (ROC) curve analyses indicated that the predictive ability of plasma NPY to distinguish CFS patients from healthy controls and from GWI was significantly better than chance alone. In 42 patients with CFS, plasma NPY had significant correlations (<0.05) with perceived stress, depression, anger/hostility, confusion, negative thoughts, positive thoughts, general health, and cognitive status. In each case the correlation (+ or -) was in the anticipated direction.Conclusions: This study is the first in the CFS literature to report that plasma NPY is elevated compared to healthy controls and to a fatigued comparison group, GWI patients. The significant correlations of NPY with stress, negative mood, general health, depression and cognitive function strongly suggest that this peptide be considered as a biomarker to distinguish subsets of CFS.",
author = "Fletcher, {Mary A.} and Martin Rosenthal and Antoni, {Michael H} and Gail Ironson and Zeng, {Xiao R.} and Zachary Barnes and Harvey, {Jeanna M.} and Barry Hurwitz and Silvina Levis and Gordon Broderick and Klimas, {Nancy G.}",
year = "2010",
month = "12",
day = "29",
doi = "10.1186/1744-9081-6-76",
language = "English",
volume = "6",
journal = "Behavioral and Brain Functions",
issn = "1744-9081",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Plasma neuropeptide Y

T2 - A biomarker for symptom severity in chronic fatigue syndrome

AU - Fletcher, Mary A.

AU - Rosenthal, Martin

AU - Antoni, Michael H

AU - Ironson, Gail

AU - Zeng, Xiao R.

AU - Barnes, Zachary

AU - Harvey, Jeanna M.

AU - Hurwitz, Barry

AU - Levis, Silvina

AU - Broderick, Gordon

AU - Klimas, Nancy G.

PY - 2010/12/29

Y1 - 2010/12/29

N2 - Background: Chronic fatigue syndrome (CFS) is a complex, multi-symptom illness with a multisystem pathogenesis involving alterations in the nervous, endocrine and immune systems.Abnormalities in stress responses have been identified as potential triggers or mediators of CFS symptoms. This study focused on the stress mediator neuropeptide Y (NPY). We hypothesized that NPY would be a useful biomarker for CFS.Methods: The CFS patients (n = 93) were from the Chronic Fatigue and Related Disorders Clinic at the University of Miami and met the 1994 case definition of Fukuda and colleagues. Healthy sedentary controls (n = 100)) were from NIH or VA funded studies. Another fatiguing, multi-symptom illness, Gulf War Illness (GWI), was also compared to CFS. We measured NPY in plasma using a radioimmunoassay (RIA). Psychometric measures, available for a subset of CFS patients included: Perceived Stress Scale, Profile of Mood States, ATQ Positive & Negative Self-Talk Scores, the COPE, the Beck Depression Inventory, Fatigue Symptom Inventory, Cognitive Capacity Screening Examination, Medical Outcomes Survey Short Form-36, and the Quality of Life Scale.Results: Plasma NPY was elevated in CFS subjects, compared to controls (p = .000) and to GWI cases (p = .000). Receiver operating characteristics (ROC) curve analyses indicated that the predictive ability of plasma NPY to distinguish CFS patients from healthy controls and from GWI was significantly better than chance alone. In 42 patients with CFS, plasma NPY had significant correlations (<0.05) with perceived stress, depression, anger/hostility, confusion, negative thoughts, positive thoughts, general health, and cognitive status. In each case the correlation (+ or -) was in the anticipated direction.Conclusions: This study is the first in the CFS literature to report that plasma NPY is elevated compared to healthy controls and to a fatigued comparison group, GWI patients. The significant correlations of NPY with stress, negative mood, general health, depression and cognitive function strongly suggest that this peptide be considered as a biomarker to distinguish subsets of CFS.

AB - Background: Chronic fatigue syndrome (CFS) is a complex, multi-symptom illness with a multisystem pathogenesis involving alterations in the nervous, endocrine and immune systems.Abnormalities in stress responses have been identified as potential triggers or mediators of CFS symptoms. This study focused on the stress mediator neuropeptide Y (NPY). We hypothesized that NPY would be a useful biomarker for CFS.Methods: The CFS patients (n = 93) were from the Chronic Fatigue and Related Disorders Clinic at the University of Miami and met the 1994 case definition of Fukuda and colleagues. Healthy sedentary controls (n = 100)) were from NIH or VA funded studies. Another fatiguing, multi-symptom illness, Gulf War Illness (GWI), was also compared to CFS. We measured NPY in plasma using a radioimmunoassay (RIA). Psychometric measures, available for a subset of CFS patients included: Perceived Stress Scale, Profile of Mood States, ATQ Positive & Negative Self-Talk Scores, the COPE, the Beck Depression Inventory, Fatigue Symptom Inventory, Cognitive Capacity Screening Examination, Medical Outcomes Survey Short Form-36, and the Quality of Life Scale.Results: Plasma NPY was elevated in CFS subjects, compared to controls (p = .000) and to GWI cases (p = .000). Receiver operating characteristics (ROC) curve analyses indicated that the predictive ability of plasma NPY to distinguish CFS patients from healthy controls and from GWI was significantly better than chance alone. In 42 patients with CFS, plasma NPY had significant correlations (<0.05) with perceived stress, depression, anger/hostility, confusion, negative thoughts, positive thoughts, general health, and cognitive status. In each case the correlation (+ or -) was in the anticipated direction.Conclusions: This study is the first in the CFS literature to report that plasma NPY is elevated compared to healthy controls and to a fatigued comparison group, GWI patients. The significant correlations of NPY with stress, negative mood, general health, depression and cognitive function strongly suggest that this peptide be considered as a biomarker to distinguish subsets of CFS.

UR - http://www.scopus.com/inward/record.url?scp=78650611350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650611350&partnerID=8YFLogxK

U2 - 10.1186/1744-9081-6-76

DO - 10.1186/1744-9081-6-76

M3 - Article

C2 - 21190576

AN - SCOPUS:78650611350

VL - 6

JO - Behavioral and Brain Functions

JF - Behavioral and Brain Functions

SN - 1744-9081

M1 - 76

ER -